The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

61

M&A and IPOs

30

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2020 (NASDAQ:ARQT)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
IPO in 2020 (NASDAQ:PASG)
IPO in 2019 (NASDAQ: PHAT)
Acquired by CutisPharma in 2019
IPO in 2020 (NASDAQ: PCVX)

Life Sciences News

Frazier Life Sciences Team

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

Frazier Lifesciences Acquisition Corporation

Frazier Lifesciences Acquisition Corporation Announces Pricing of Upsized $120 Million Initial Public Offering

Frazier Life Sciences Team

Frazier Healthcare Partners Adds Two Senior R&D Leaders to Life Sciences Team

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

View All News